The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 30, 2023

Filed:

Apr. 13, 2022
Applicant:

Liquidia Technologies, Inc., Morrisville, NC (US);

Inventors:

Robert Frank Roscigno, Melbourne Beach, FL (US);

Brian T. Farrer, Apex, NC (US);

Jacob J. Sprague, Cary, NC (US);

Benjamin Maynor, Durham, NC (US);

Assignee:

LIQUIDIA TECHNOLOGIES, INC., Morrisville, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61P 9/12 (2006.01); A61K 31/557 (2006.01); A61K 9/48 (2006.01); A61K 31/5575 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01);
U.S. Cl.
CPC ...
A61K 31/557 (2013.01); A61K 9/0075 (2013.01); A61K 9/4858 (2013.01); A61K 31/5575 (2013.01); A61P 9/12 (2018.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01);
Abstract

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.


Find Patent Forward Citations

Loading…